Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387465 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
A Phase 1 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 5
- Study locations
NCT00387465 is a Phase 1 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 94 participants, below the 685-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT00387465, a Phase 1 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase I/II trial is studying the side effects and best dose of azacitidine when given together with entinostat and to see how well they work in treating patients with recurrent advanced non-small cell lung cancer. Azacitidine and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with entinostat may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Entinostat
- DRUG Azacitidine 30mg/m2
- DRUG Azacitidine 40mg/m2
Study Locations (5)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital - Baltimore
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center - Baltimore
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Sidney Kimmel Cancer Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2006-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387465
The ClinicalTrials.gov registry entry for NCT00387465 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 685-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (86% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Entinostat is the first listed.
NCT00387465 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Maryland, California.
Frequently Asked Questions
What is clinical trial NCT00387465 about?
NCT00387465 is a clinical study titled "Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer". This phase I/II trial is studying the side effects and best dose of azacitidine when given together with entinostat and to see how well they work in treating patients with recurrent advanced non-small cell lung cancer. Azacitidine and entinostat may stop the growth of tumor cells by blocking some of...
What is the current status of trial NCT00387465?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2006-08. Estimated completion is 2014-11.
What conditions does trial NCT00387465 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT00387465?
The interventions under investigation include: Entinostat (DRUG), Azacitidine 30mg/m2 (DRUG), Azacitidine 40mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00387465?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00387465 being conducted?
This trial has 5 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Stage IV Non-small Cell Lung Cancer
All registered trials for this condition
Stage IIIB Non-small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.